Abstract
Kymera Therapeutics has raised $102 million in a series C financing round led by Biotechnology Value Fund and Redmile Group. Kymera, one of C&EN’s 10 Start-Ups to Watch in 2018, designs small molecules that bind tough-to-drug proteins and tags them for destruction in the cell’s proteasome. CEO Nello Mainolfi says the new funds could help the firm start clinical testing for up to three of its programs by next year. Kymera’s lead drug candidate targets IRAK4, a protein involved in inflammation and autoimmune diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
